BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:CfEL's Enterprise Tuesday 2011/2012: Serendipity or Hard Work - Dr
  David Brown FRSC\, Managing Director of Alchemy Biomedical Consulting
DTSTART:20111115T180000Z
DTEND:20111115T210000Z
UID:TALK33957@talks.cam.ac.uk
CONTACT:Enterprise Tuesday
DESCRIPTION:The session on *15th November* is about innovation in the busi
 ness world and the role played by 'intrapreneurs' in taking discoveries to
  market. It tracks the progress of two block buster drugs – *Viagra and 
 Relpax*. \n\n*Dr David Brown* is a scientist\, intrapreneur and has held m
 any senior positions in the Bio/Pharma industry. He has a truly distinguis
 hed record of not only doing the science\, but also of taking key discover
 ies to market. Dr Brown is one of the patent holders of that 'accidental' 
 discovery *Viagra*\, one of the biggest brand names of recent years.  He i
 s also part of the team that actually made it a commercial success taking 
 it through the early years of drug efficacy trials.\n\n*When?* 15th Novemb
 er 2011. Registration is from 18:00. The lecture starts at 18:30. Networki
 ng from 20:00. Refreshments are provided.\n\n*Where?* University of Cambri
 dge Department of Engineering\, LT0 \, Trumpington Street\, Cambridge\n\n*
 Registration:* Please register online at http://www.cfel.jbs.cam.ac.uk/pro
 grammes/enterprisetuesday/register.html\n\n*Dr David Brown FRSC*\, Managin
 g Director of Alchemy Biomedical Consulting\n\nDr David Brown has over 30 
 years experience in the pharmaceutical / biotechnology industry both in re
 search and in senior executive roles. He served with 4 of the top 10 pharm
 aceutical companies: Zeneca\, Pfizer\, GlaxoWellcome\, and Hoffman La-Roch
 e\; and also as President and Chief Executive of Cellzome AG. Whilst at Pf
 izer he was named co-inventor on the patent for Viagra\, a treatment for m
 ale impotence\, and he led the team that developed it. The drug is also ma
 rketed for treatment of Pulmonary Hypertension under the trade name Revati
 o. He also had a pivotal role in the discovery of Relpax\, a treatment for
  migraine. While at Roche in Switzerland\, he was a Director of the compan
 y and had responsibility over 2000 staff focused on drug discovery.\n\nSin
 ce 2005 Dr Brown has pursued a portfolio of roles dedicated to bringing ne
 w medical treatments to both the developed and developing world. He has be
 en heavily involved with OneWorld Health\, San Francisco\, where his work\
 , and that of the organization\, is dedicated to bringing medicines to the
  poorest of the poor in the world. In particular he has been responsible f
 or development of a global strategy to reduce child deaths from diarrheal 
 diseases etc. This work has been funded by Bill Gates through his charitab
 le trust. In the developed world\, his work focuses mostly on finding brea
 kthrough treatments for bone disorders and also on different types of pain
 . He is an Honorary Fellow in Human Clinical Pain at Manchester University
 .\n\nDr Brown has extensive experience of leadership at both Chief Executi
 ve and Board level. He has previously served on the boards of Cellzome AG 
 in Germany and the Institute for One World Health in San Francisco. He cur
 rently serves on the boards of Crescendo Biologics\, Amura Ltd and Indigix
  Ltd and is Chair of Babraham Biotechnologies Ltd. He is also Chair of the
  Scientific Advisory Board of Heptares Ltd. He is also co-founder and Chai
 rman of a charity (FMVSO) supporting a school and orphanage for destitute 
 children in India.\n\n\nFurther information about the Enterprise Tuesday s
 eries is available at http://www.cfel.jbs.cam.ac.uk/programmes/enterpriset
 uesday/programme/timetable.html
LOCATION:Lecture Theatre 0\, Department of Engineering\, Trumpington Stree
 t
END:VEVENT
END:VCALENDAR